Barron’s is bullish on Chevron and Corning

Barron’s, the weekly publication owned by the Wall Street Journal, in its latest issue mentions several names: 

Stockwinners offers Barron's review of Stockwinners offers stocks to buy, stocks to watch, upgrades, downgrades, earnings, Stocks to Buy On Margin
Stockwinners offers Barron’s review of stocks to buy

BULLISH  MENTIONS

Chevron positioned to benefit in 2018 – No oil major is better positioned to benefit than Chevron (CVX) in 2018, who said it would spend about $18B next year while it starts to reap the benefits from the big projects that had been consuming cash since 2011, Ben Levisohn writes in this week’s edition of Barron’s.

Corning shares could gain over 25%– Shares of Corning (GLW) could keep climbing as demand grows for optical fiber, LCD-panel glass, and Gorilla Glass, Leslie Norton writes in this week’s edition of Barron’s.

Facebook could consider cash dividend – None of the fast-growing giants, namely Facebook (FB), Amazon (AMZN), Netflix (NFLX) and Alphabet (GOOG; GOOGL), pay a cash dividend, but that may change before long, Jon Swartz writes in this week’s edition of Barron’s. Facebook is pushing up against the limits of growth, and if growth begins to taper, investors will begin calling for new strategies, such as dividends and stock buybacks, he notes. Several factors make Facebook the most likely FANG candidate to offer a dividend, perhaps as early as 2019, including sufficient earnings, Swartz contends.

 ‘Good time’ to buy GlaxoSmithKline stock.  GalxoSmithKline’s (GSK) earnings estimates have been sliding and shares have tumbled since the summer, but now looks like a good time to buy the stock, Jack Hough writes in this week’s edition of Barron’s. While GlaxoSmithKline will suffer an earnings hit in 2018 from new generic competition, it should get back on track quickly, he contends.

BEARISH MENTIONS

Some retail stocks look vulnerable – In a follow-up story, Barron’s says that prudent investors should assume that the recent burst of sunshine will give way to more rainy days for retail. Macy’s (M) may look inexpensive but its earnings per share are expected to tumble in each of the next two years, J.C. Penney (JCP) is in a long-term fight for its existence, Sears Holdings (SHLD) makes the former look like Amazon (AMZN), and Abercrombie & Fitch (ANF) sells a deflationary good at a dying venue against a fashion headwind, the report added. On the other hand, Barron’s argued that Wal-Mart’s (WMT) improvement remains intriguing, Home Depot (HD) and TJX (TJX) remain long-term winners, and Five Below (FIVE) seems to be a genuine fast-grower.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Allergan receives $290 million in damages

Pershing to pay $193.75M, Valeant to pay $96.25M to settle lawsuits

Watch Allergan into better botox data. See Stockwinners.com
Allergan receives $290 million in damages

Pershing Square announced that it has reached an agreement in principle, subject to court approval, to settle lawsuits concerning the attempted acquisition of Allergan (AGN) by Pershing Square Capital Management and Valeant Pharmaceuticals (VRX) in 2014, which were filed in the Central District of California.

Pershing Square and Valeant have agreed to split the $290M total settlement such that Pershing Square will pay $193.75M and Valeant will pay $96.25M.

Pershing says, “While Valeant had originally agreed to pay 60% of the cost of the settlement, Valeant and Pershing Square had different views on the desirability and timing of settling the case, which previously prevented settlement.

On December 19, 2017, Pershing Square acquired control of the settlement of the litigation in exchange for agreeing to pay a greater percentage of the settlement amount.”

Pershing Square CEO Bill Ackman adds, “We continue to believe the case had absolutely no merit. We decided, however, that it was in the best interest of our investors to settle the case now instead of continuing to spend substantial time and resources pursuing the litigation.”

Pershing Square had previously set aside $75M in legal reserves related to the case. The incremental cost of settling the litigation will reduce the company’s and the private funds’ performance and net asset value by 132 basis points.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Progenics Pharma announces FDA acceptance of NDA for AZEDRA

Progenics announces FDA acceptance of NDA for AZEDRA

Progenics announces FDA acceptance of NDA for AZEDRA. Stockwinners
Progenics announces FDA acceptance of NDA for AZEDRA

Progenics Pharmaceuticals (PGNX) announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for AZEDRA in patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma, which are rare neuroendocrine tumors.

Pheochromocytoma and paraganglioma are rare tumors that form from neuroendocrine cells. Neuroendocrine cells release hormones into the blood when they receive a signal from the nervous system. Neuroendocrine cells are found all through the body.

Paragangliomas usually form near the carotid artery and along nerve pathways in the head, neck, and spine. Pheochromocytomas form in the adrenal medulla (the center of the adrenal gland found on top of each kidney).

Certain inherited disorders increase the risk of pheochromocytoma or paraganglioma. These include multiple endocrine neoplasia 2 syndrome, types A and B , von Hippel-Lindau syndrome, and neurofibromatosis type 1.

Pheochromocytomas and paragangliomas may be benign or malignant.

The FDA granted Progenics’ request for Priority Review and has set an action date of April 30, 2018 under the Prescription Drug User Fee Act (PDUFA).

The NDA is supported by data from a pivotal phase 2b open-label, multi-center trial that was conducted under a Special Protocol Assessment with the FDA.

The trial met the primary endpoint evaluating the proportion of pheochromocytoma and paraganglioma patients who achieved a 50% or greater reduction of all antihypertensive medication for at least six months, and showed favorable results from a key secondary endpoint evaluating the proportion of patients with overall tumor response as measured by Response Evaluation Criteria In Solid Tumors.

AZEDRA was also shown to be safe and generally well tolerated.

PGNX closed at $5.85. It last traded at $7.20 in pre-market trading.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Renren acquires U.S. trucking platform Trucker Path

Renren acquires U.S. trucking platform Trucker Path

Renren acquires U.S. trucking platform Trucker Path. Stockwinners
Renren acquires U.S. trucking platform Trucker Path
Renren (RENN) announced that it has entered into a definitive agreement to acquire 100% of Trucker Path Inc., a provider of a social platform for the trucking industry in the United States.

 

Trucker Path’s core product is the Trucker Path app, a trip planning companion for truck drivers, enabling a large driver community to assist each other in updating the real-time status of relevant points-of-interest on their route.
It helps truckers find truck stops, available parking spots, rest areas, scales, open DOT weigh stations, truck washes and more. Expanding on the success of the Trucker Path app, Trucker Path also introduced the Truckloads app, a mobile marketplace providing freight load matching with over 3 million loads posted monthly.

 

At present, Trucker Path has more than 600,000 monthly active users covering more than 33% of all U.S. long haul truck drivers and maintains steady organic growth.

 

For Renren’s global business, the acquisition of Trucker Path means an entry into the transportation sector. Going forward, Renren will continue exploring breakthroughs in this space, whether in intelligent transportation solutions or in autonomous vehicles.

RENN closed at $10.59.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

 

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.


Biotech stocks to watch in January

Ten biotech names to watch in January 

Biogen says BAN2401 did not meet primary endpoint. Stockwinners.com

In a research note to investors, Jefferies analyst Michael #Yee identified what he sees as ten potential disclosures or announcements that could come in the next two weeks to start 2018.

Stockwinners offers stocks to buy, stocks to watch, upgrades, downgrades, earnings, Stocks to Avoid

Among the names that may see stock-moving events as the new year begins are Celgene (CELG), Biogen (BIIB) and Vertex (VRTX).

TURNING THE PAGE TO 2018

Jefferies’ Yee told investors that “turning the page to 2018 and into a January conference,” he is modestly optimistic that large-cap biotech picks up a bit given the recent pullback, tax reform and low investor expectations.

He reiterated that the big biotech names are working toward a much bigger 2018 product cycle and late-stage data read out period.

Celgene tumbles

Thinking outside of the box, the analyst pointed out that the key upside “wild-card” is whether “big consolidation” actually occurs in the large caps based on pharmaceutical companies buying pharma or “big biotech” companies.

STOCK-MOVING ANNOUNCEMENTS

Other than surprise M&A deals that could swing sentiment in biotech, Jefferies’ Yee sees the potential for at least ten stock-moving announcements within his coverage going into a major industry conference in two weeks.

The analyst told investors that #Celgene is likely to pre-announce results for its fourth quarter and provide new 2018 guidance, though investors should assume that outlook could be conservative.

#Biogen could also disclose color around Spinraza patient numbers and update on aducanumab Alzheimer’s enrollment, he contended.

Yee argued that #Vertex could pre-announce on its fourth quarter but may not provide 2018 Cystic Fibrosis guidance until its ‘661 combo is approved in February. The company could also disclose Phase 3 triple plans and update on Phase 2 data.

Regarding #Alnylam Pharmaceuticals (ALNY), the analyst highlighted the company may discuss the path forward for ALN-TTRsc02, update on the ALN-GO1 phase 1 program, or announce a new program in the near-term.

#AveXis (AVXS) may provide FDA meeting updates and next steps post recent regulatory discussions; Intercept Pharmaceuticals (ICPT) may pre-announce fourth quarter Ocaliva sales or announced the initiation of a Phase 3 cirrhosis study, or give color on upcoming FDA label change; and Assembly Biosciences (ASMB) could announce Phase 1b HBV data on viral knockdown, he contended.

stockwinners.com ICPT

Lastly, Yee pointed out that Axovant Sciences (AXON) may report Phase 2B data for intepiridine in dementia with Lewy bodies and nelotansersin in visual hallucinations, while Acorda Therapeutics (ACOR) is likely to pre-announce 2017 Ampyra net sales and provide 2018 financial guidance, and FibroGen (FGEN) could disclose HRCT imaging IPF data or Phase 2 pancreatic cancer data for pamrevlumab.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Bitcoin drops after S. Korea requires real name in crypto trading

S. Korea to require real-name accounts in crypto trading

Bitcoin hits $8000. See Stockwinners.com for details
Bitcoin lower after S. Korea requires real name for crypto trading

Hong Nam-ki, South Korean minister of the Office for Government Policy Coordination, announced the country would ban the use of anonymous virtual accounts in cryptocurrency transactions as the government “can’t let this abnormal situation of speculation go on any longer,” the Korea Herald reports, citing the announcement.

Under the ban only real-name back accounts and matching virtual accounts can be used for deposits and withdrawals, while exchanges will be banned from issuing new virtual accounts to clients.

Bitcoin-related names Overstock (OSTK), Digital Power (DPW), Long Blockchain (LTEA), Seven Stars Cloud Group (SSC), Riot Blockchain (RIOT), Longfin (LFIN), Social Reality (SRAX) and Parateum (TEUM) are all trading lower in the pre-market and heading for a second straight big down day as Bitcoin extends its slide overnight below $14,000.

Speculation over South Korea regulators considering options that could include a shutdown of some cryptocurrency exchanges is fueling today’s decline. The cryptocurrency is now down over 25% from last week’s record high.

Riot Blockchain (RIOT) drops, levels to watch.  The stock was last down over 6% to $28 in pre-market trading following news that the South Korean government may seek to regulate cryptocurrencies. Bitcoin fell sharply in the wake of that news, last down over 7.2%, which is off the earlier drop of more than 10%. At the current price of $28, next support is at $26.12.

After forming a high of $16,416 this week, the cryptocurrency came under a selling pressure as traders showed their reaction to South Korea’s news. The country is determined to curb the speculative market and it would take measures to stop and review various crypto-exchanges.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Cannabis in California

Names to watch ahead of California marijuana legalization

Names to watch ahead of California marijuana legalization. Stockwinners.com
Names to watch ahead of California marijuana legalization

As recreational use of marijuana is set to become legal in California on the first day of the year, the space seems to be getting more and more attention, with a new marijuana ETF starting to trade this week and Constellation Brands (STZ) taking a stake in a Canadian medical marijuana producer earlier this year.

CANNABIS IN CALIFORNIA

For people residing in California, the New Year means they will able to buy recreational marijuana as it is set to become legal in the state starting January 1, a date that dispensaries and consumers have had in their sights on since Proposition 64 made it the official opening of the adult-use market in California.

In keeping with state rules, retailers will be able to sell or deliver cannabis between 6am and 10pm.

NAMES TO WATCH

Among the publicly traded names in the space is Innovative Industrial Properties (IIPR), a REIT that owns dispensary properties.

Last year, NYSE became the first major exchange to list a cannabis company with its acceptance of Innovative Industrial Properties’ initial public offering.

Constellation Brands seems to also be interested in the blossoming cannabis industry as the company bought a minority stake in a Canadian medicinal marijuana producer.

In October, Constellation announced it paid C$245M for a 9.9% interest in Canopy Growth, a Canadian provider of medicinal cannabis products.

Constellation, which is looking to develop cannabis products that don’t contain alcohol, does not expect to sell products in the U.S. before marijuana is nationally legalized but may begin to sell products in Canada, where such products are expected to be legalized by 2019.

Earlier this week, ETF Managers Group announced that MJX, the ETFMG Alternative Harvest ETF, was live and available for trading on the NYSE Arca.

This fund is one of the first of its kind available to U.S. investors and is designed to replicate the Prime Alternative Harvest Index, which tracks companies likely to benefit from the increasing global acceptance of various uses of the cannabis plant.

This includes treatments from innovative medicinal breakthroughs involving the plant’s unique properties.

PRICE ACTION

In Wednesday’s trading, shares of Constellation Brands are fractionally down to $224.95, while Innovative Industrial Properties is up nearly 5% to $27.24.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Brigade Capital takes stake in Kindred, opposes takeover by Humana

Brigade Capital takes 5.8% stake in Kindred, opposes takeover

Kindred Health sold for $9 a share. Stockwinners
Brigade Capital takes 5.8% stake in Kindred, opposes takeover

Brigade Capital disclosed a 5.8% stake in Kindred Healthcare (KND) and expressed opposition to the company’s proposed buyout by TPG Capital, Welsh, Carson, Anderson & Stowe and Humana (HUM).

Representatives of Brigade intend to engage in discussions with Kindred’s management and board regarding, among other things, the company’s strategic alternatives and direction, and strategies to enhance shareholder value, including regarding the recently announced proposed acquisition.

On December 27, Brigade delivered a letter to the board stating its opposition to the takeover and noting the “material inadequacy of the terms of the proposed transaction.”

Brigade’s belief is that the $9.00 per share cash merger price “significantly undervalues” Kindred’s common stock. The Letter notes that from the perspective of maximizing shareholder value, Brigade believes it is premature for Kindred to engage in a sale transaction.

Over the past year, Brigade noted that the company “has overcome numerous challenges and calmed most of the headwinds against its business, positioning it for substantial stock price appreciation in 2018 and beyond.”

The activist added, “Brigade expected management to continue operating the business to enable the shareholders who have patiently supported the Issuer throughout its challenges to realize the benefits of the business improvements through their continued ownership in the going concern.

Instead, Brigade stated in the Letter, that it believes management has chosen to pursue a transaction with the Consortium that severely undervalues the Issuer and ensures that the Consortium – rather than existing shareholders – will reap the benefits of the value enhancement the improved business is expected to generate.

For these and the reasons stated in the Letter, Brigade advised the Issuer that it does not believe the proposed transaction is in the best interests of the Issuer’s shareholders and intends to actively oppose it.”

BACKGROUND

On December 19th,  Kindred Healthcare (KND) announced that its Board of Directors has approved a definitive agreement under which it will be acquired by a consortium of three companies: TPG Capital, Welsh, Carson, Anderson & Stowe and Humana (HUM) for approximately $4.1B in cash including the assumption or repayment of net debt.

Under the terms of the agreement, Kindred stockholders would receive $9.00 in cash for each share of Kindred common stock they hold, representing a premium of approximately 27% to Kindred’s 90-day volume weighted average price for the period ending December 15, 2017, the last trading day prior to media reports regarding the potential transaction.

KND last traded at $9.42, two cents up on the day.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Energous receives FCC certification for power-at-a-distance device

Energous receives FCC certification for power-at-a-distance device

Energous jumps after reporting FCC certification for power-at-a-distance device. Stockwinners.com
Energous receives FCC certification for power-at-a-distance device
Shares of Energous Corporation (WATT) are surging in pre-market trading after the company announced last night that the Federal Communications Commission has awarded certification of its first-generation WattUp Mid Field transmitter, which sends focused, RF-based power to devices at a distance.
“As the first FCC certification for power-at-a-distance wireless charging under Part 18 of the FCC’s rules, this development represents a new era of wireless charging, and opens up a tremendous opportunity for the electronics industry,”
the company stated in its press release announcing the certification.
Shares of small-cap Energous, which have frequently been volatile in the past around product announcements or reports implicating that the company may win a contract with a smartphone maker, are up $9.30, or 105%, to $18.14 in pre-market trading.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.


Anika Therapeutics receives FDA clearance for bone void filler

Anika Therapeutics receives FDA 510(k) clearance for HA-based bone void filler

Anika Therapeutics says Monovisc approved in India. See Stockwinners.com Market Radar for Stock Upgrades, stock downgrades, stock earnings, stocks to watch
Anika Therapeutics receives FDA 510(k) clearance for HA-based bone void filler

Anika Therapeutics (ANIK) announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Administration and is indicated for filling bone voids or defects of the skeletal system, which are not intrinsic to the stability of the bone, created during surgery or resulting from traumatic injury.

HA-based bone  stands for therapeutics based on its proprietary hyaluronic acid (“HA”) technology. The bone void filler, which is composed of a synthetic, biocompatible bone graft substitute material, is injected into a void, hardens at body temperature, and is then resorbed and replaced by the growth of new bone during the healing process.

Over one million musculoskeletal procedures performed in the U.S. involve bone void filling, also known as bone grafting,, and such procedures are most commonly required for spinal fusion, trauma, and revision total joint replacement procedures.

While the use of autologous bone or autograft has been the gold standard of treatment for bone grafting, the increased risk of procedural complications has prompted a shift towards alternate treatments, such as synthetic, resorbable bone graft substitute materials.

The company estimates that the current market size for treating tibial plateau fractures, stress fractures around joints, and decompression of necrosed bone to be around $300M.

ANIK closed at $52.44.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Nova Lifestyle enters blockchain frenzy

Nova Lifestyle to launch blockchain-based digital community

Nova Lifestyle enters blockchain frenzy. Stockwinners.com
Nova Lifestyle enters blockchain frenzy

Nova LifeStyle (NVFY) announced that the company has initiated design of a digital community that brings together designers and customers to deliver real time product and user experience built on Blockchain-empowered technology platform named The iDesign Blockchain Platform, which it believes to be a first in the furniture industry.

“iDesign Blockchain Technology Inc.,” a Nova LifeStyle subsidiary intends to establish a trusted digital ecosystem that links the experiences of independent product designers, customers and manufacturers with Nova-branded products on a creative global digital platform powered by Blockchain technology.

The iDesign Blockchain Technology Platform plans to target various artistic creator or designer as an innovation center, focusing on their ideation process to deliver enhanced user experience.

The company will implement these new initiatives with cash flow from existing operations.

Nova LifeStyle, Inc.  designs, manufactures, markets, and sells residential furniture for middle and upper middle-income consumers worldwide. The company develops upholstered, wood, and metal-based residential furniture for the living rooms, dining rooms, bedrooms, and home offices. It also offers sofas, chairs, dining tables, beds, entertainment consoles, cabinets, and cupboards.

CRYPTO TREND

Cryptocurrency revenues have been pointed to as reasons to be bullish on Advanced Micro Devices (AMD) and Nvidia (NVDA) in select research. Overstock (OSTK), Digital Power (DPW), Long Blockchain (LTEA), Seven Stars Cloud Group (SSC), Riot Blockchain (RIOT), Longfin (LFIN) and Social Reality (SRAX) are other stocks that have been touted, or promoted themselves, as a way to play the crypto theme.

NVFY closed at $2.51. It last traded at $2.95 in pre-market trading.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Pareteum soars on cryptocurrency billing

Pareteum adds Blockchain settlement for cryptocurrency to platform

Cryptocurrency mania continues as the bitcoin bubble expands

Pareteum-Corp soars on cryptocurrency billing - Stockwinners.com
Pareteum soars on cryptocurrency billing

Pareteum Corp. (TEUM) announced that it has completed development enabling it to add support of Blockchain technology to its billing and settlement services.

“This newest service capability enables Pareteum customers to participate in the transformational ‘Digital Economy Monetization to the Cloud’ and now accept and process Bitcoin, Ethereum, Litecoin, Airtokens and other forms of cryptocurrencies,” said the company, whose share were halted pending the news release.

Hal Turner, Executive Chairman and Principal Executive Officer of Pareteum, added:

“We envision a time in the not too distant future when Pareteum could create its own currency payments and settlements among the millions of subscribers on its platform globally.

As we consider the new global mobile landscape, and Pareteum’s service and capabilities developments in 2017, which have opened doors for us in the Internet of Things, Smart Cities, and use of Artificial Intelligence and Machine Learning creating predictive analytics for the vast amounts of digital data we are capable of securely processing, we maintain an optimistic view towards 2018 and beyond.”

CRYPTO TREND

Cryptocurrency revenues have been pointed to as reasons to be bullish on Advanced Micro Devices (AMD) and Nvidia (NVDA) in select research. Overstock (OSTK), Digital Power (DPW), Long Blockchain (LTEA), Seven Stars Cloud Group (SSC), Riot Blockchain (RIOT), Longfin (LFIN) and Social Reality (SRAX) are other stocks that have been touted, or promoted themselves, as a way to play the crypto theme.

Pareteum (TEUM) jumps 99% to $2.54 after adding blockchain technology.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Boston Omaha jumps on Buffett connection

Boston Omaha rises after WSJ profile highlights link to Buffett

Stockwinners offers real time news and information
Boston Omaha jumps on Buffett connection

Shares of billboard advertisement seller and surety insurer Boston Omaha (BOMN) are rising following a Friday profile of the company in the Wall Street Journal.

SHARES DOUBLE SINCE LISTING

Shares of Boston Omaha, which is run by co-CEOs Alex Buffet Rozek and Adam Peterson, have more than doubled since listing on the Nasdaq Stock Market in June.

The company, which recently reported third quarter revenue of $2.4M, has a market capitalization of over $447M with today’s advance.

Rozek, who is Warren Buffett’s grandnephew, said the company receives no assistance from Buffett or Berkshire Hathaway (BRK.A, BRK.B) and does not advertise the link as he wants Boston Omaha’s results to stand on their own.

boston omaha shares jump on Buffett connection. Stockwinners.com
Boston Omaha shares jump on Buffett connection.

“It’s not like there’s this private class that goes on for family members about business,” Rozek said.

“If I wanted to learn, the best thing I could do is pick up an annual report and read the Berkshire annual report like anybody else.”

Buffett, who doesn’t own Boston Omaha stock, said, “I think the world of Alex, but we don’t have anything to do with his decision-making or anything of the sort. He’s got a good mind, a very good mind, and he certainly has good values.”

Boston Omaha, however has shown some similarities to Berkshire, including an acquisition focus on companies with consistent earnings and strong competitive positions, running acquired companies independently and skipping earning calls for an annual meeting.

The company, which does not currently invest in stocks, is 55% owned by Peterson’s Magnolia Group and 12% owned by Rozek’s Boulderado Group and other entities he manages.

PRICE ACTION

Boston Omaha is up 20.1%, or $5.69, to $34.02 in Tuesday’s trading. Including Friday’s advance, the stock is up over 33% over the last two sessions.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Hubbell to acquire Aclara Technologies for $1.1B

Hubbell to acquire Aclara Technologies for $1.1B

Hubbell to acquire Aclara Technologies for $1.1B. Stockwinners.com
Hubbell to acquire Aclara Technologies for $1.1B

Hubbell (HUBB) announced that it has entered into a definitive agreement to acquire Aclara Technologies, an affiliate of Sun Capital Partners for approximately $1.1B in an all- cash transaction.

Hubbell Incorporated designs, manufactures, and sells electrical and electronic products in the United States and internationally.

The transaction strengthens and broadens Hubbell Power Systems’ competitive position across utility markets.

The acquisition will combine the complementary strengths of Aclara and Hubbell Power Systems, providing the opportunity to integrate Aclara’s strong customer relationships and smart infrastructure solutions into the Hubbell portfolio and accelerate ongoing innovation efforts to address utility customer demand for data and integrated solutions.

Aclara offers a comprehensive suite of solutions, including advanced metering infrastructure, meters and edge devices, software, and installation services.

Aclara reported revenues of $500M and adjusted EBITDA of $90M for the fiscal year ended September 30, 2017.

The transaction is expected to be accretive in 2018 to Hubbell’s diluted EPS, excluding intangible amortization and deal related costs, and in 2019 on a GAAP basis.

Further, Hubbell expects to maintain an investment grade rating. Hubbell has obtained fully committed bridge financing from J.P. Morgan Securities, BofA Merrill Lynch, and HSBC Securities.

Hubbell expects its debt-to-adjusted EBITD ratio to be 3.1x at the close of the transaction, and anticipates reducing this ratio over the next few years.

The transaction, which is expected to be completed in 1Q18, is subject to the satisfaction of customary closing conditions, including U.S. antitrust clearance.

HUBB closed at $135.23.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Apple lower on soft iPhone X demand

Apple slides as Taiwanese report raises fears about iPhone X

Stocks to Buy, Stocks to Buy on Margin, Stocks to invest in, stocks to own
Apple lower on weak iPhone X demand

Apple (AAPL) shares are weaker as U.S. investors return from the long holiday weekend after a Taiwanese newspaper report said the tech giant is trimming its first-quarter sales forecast, according to Bloomberg.

Adding to the caution are analysts following suit, reportedly due to worries about demand for the high-end iPhone X.

ANALYSTS, APPLE SAID TO TRIM FORECASTS

Taiwanese newspaper Economic Daily News quoted unidentified supply chain officials as having said that Apple is lowering its first-quarter iPhone sales forecast to 30 million units from 50 million, according to Bloomberg.

It also said Hon Hai Precision Industry Co.’s main iPhone X manufacturing hub in Zhengzhou, China, stopped recruiting workers. The company also known as Foxconn is the sole iPhone X assembler, and also makes the handsets in Shenzhen and Chengdu.

An Apple representative declined to comment on production decisions, the report noted.

Additionally, Bloomberg noted that analysts at New York-based JL Warren Capital and China’s Sinolink Securities have each lowered iPhone X shipment projections for the first quarter of next year.

Apple has been counting on a redesigned 10th anniversary iPhone to boost shipments as its market value advances toward $1 trillion. The Cupertino, California-based company is facing new challenges from Samsung Electronics Co., which is quickly recovering from the Galaxy Note 7’s recall after fires. In the meantime, Chinese brands such as Huawei, Oppo and Xiaomi are also luring away potential customers in China and other emerging markets such as India.

SUPPLIERS TO WATCH

Suppliers to Apple that may be volatile following Bloomberg’s cautious report regarding signs of slack iPhone X demand include Skyworks (SWKS), Cirrus Logic (CRUS), Broadcom (AVGO), Qorvo (QRVO), Qualcomm (QCOM), STMicroelectronics (STM), Analog Devices (ADI), Knowles (KN) and Micron (MU).

PRICE ACTION

In pre-market trading, Apple shares are down $4.73, or 2.7%, to $170.28.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.